NeurAegis Inc Profile last edited on: 3/11/2024
CAGE: 7PKW7
UEI: Z9HYPA6YLBJ3
Business Identifier: Novel Protease Inhibitors for the Treatment of Neurological Disorders 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 47
County: Orange
Congr. District: 47
County: Orange
Public Profile
NeurAegis, Inc. is a late preclinical stage neuropharmaceutical company pioneering the development of breakthrough treatments for neurological disorders including traumatic brain injury (TBI)/concussion and epilepsy. Firm's initial focus is developing first-in-class, novel protease inhibitors for TBI where there are currently no FDA approved treatments.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2024 | 2 | NIH | $706,597 | |
| Project Title: Testing the effects of a selective calpain-2 inhibitor on spontaneous recurrent seizures in mouse models of epilepsy | ||||
Key People / Management
Michel Baudry -- Founder & Chief Scientific Advisor
Stella M Sung -- President & CEO
Philippe Bey -- Chemistry
Kathy Fosnaugh -- Program Management
Shujaath Mehdi -- Biochemical Pharmacology
Michael Palfreyman -- Drug Development Advisor
Stella M Sung -- President & CEO
Philippe Bey -- Chemistry
Kathy Fosnaugh -- Program Management
Shujaath Mehdi -- Biochemical Pharmacology
Michael Palfreyman -- Drug Development Advisor
Company News
There are no news available.
